Listen to this Blog Talk Radio interview with your Hosts:
Stuart Schlossman and Deanna Kirkpatrick
as we Interviewed:
Dr. James Yarger, a researcher about Inducing Re-Myelination using NDC-1308
LISTEN to this Interview by clicking here
ENDECE Neural recently published data showing that NDC-1308 induces a dramatic upregulation of genes in signaling pathways involved in myelin sheath production. Here, Dr. Nye will present new data from studies in mice showing that NDC-1308 demonstrates:
• Significant remyelination in both the hippocampal and cortical brain regions using a mouse model of demyelination, in which the neurotoxicant cuprizone was used to remove the myelin sheath from the axons (nerve fibers) of mice
• Rapid absorption into target tissues of the central nervous system (CNS)
• A favorable safety profile
Additionally, the company has laid out a proposed timeline to the clinic for NDC-1308, including plans to initiate Phase 1 clinical trials in 2015.
About NDC-1308
NDC-1308 is a novel chemical entity designed to address one of the root causes of MS, and is being developed for potential use either alone or in combination with other MS therapeutics that slow the progression of the disease. By controlling key genes in pathways leading to myelin synthesis, NDC-1308 appears to induce restoration of the lost myelin sheath that is believed to cause the devastating symptoms of MS. NDC-1308 is a small molecule that readily crosses the blood-brain barrier, allowing it to reach the tissues in the brain and spinal cord where promoting myelin production is needed. NDC-1308 works by inducing differentiation of oligodendrocyte progenitor cells (OPCs) into mature oligodendrocytes, cells that synthesize and maintain the myelin sheath. ENDECE Neural discovered NDC-1308, and owns the intellectual property surrounding the compound.
About ENDECE Neural
ENDECE Neural is a private biotechnology company at the forefront of developing therapies to repair and potentially reverse damage caused by devastating neurological diseases such as MS. A wholly owned subsidiary of ENDECE LLC, ENDECE Neural was founded in 2011 to focus on the development of what could be the first drug capable of inducing remyelination of damaged nerves in patients with MS. The company is leveraging decades of accumulated knowledge about how activation of estrogen receptors in a specific manner affects gene regulation. Researchers at ENDECE Neural have identified small-molecule compounds that upregulate key genes in pathways involved in promoting myelin sheath synthesis. ENDECE Neural is developing NDC-1308, which appears to directly induce OPCs to differentiate into mature oligodendrocytes that restore the depleted myelin sheath in rodent models. ENDECE Neural discovered and owns the intellectual property surrounding its compounds, and the company’s management team has a track record of successfully taking products from the laboratory through FDA approval and commercial release.
…….
Share our Articles with others
